Category: Thoratec Corp.Syndicate content

Thoratec's Q4, 2014 earnings beat forecasts

February 11, 2015 by Brad Perriello

Thoratec reports higher-than-forecast earnings for the 4th quarter and 2014, on an extra selling week and higher utilization rates for its implantable heart pumps, and says it will narrow its focus to the ventricular assist device market.

Thoratec's Q4, 2014 earnings beat forecasts

Thoratec (NSDQ:THOR) yesterday reported higher-than-forecast earnings for the 4th quarter and 2014, crediting an extra selling week and better utilization rates for its implantable heart pumps.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Thoratec completes enrollment in HeartMate III study

December 1, 2014 by Val Kennedy

Thoratec completes enrollment in a European clinical trial for its HeartMate III left ventricular assist device.

Thoratec completes enrollment in HeartMate III study

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

LVAD slump? Thoratec dims outlook after Q3 earnings plunge

November 6, 2014 by Brad Perriello

Thoratec's 3rd-quarter earnings plunge nearly 85% as sales decline more than 16%, raising fears that the left ventricular-assist device market is in a slump that could persist into 2015.

LVAD slump? Thoratec dims outlook after Q3 earnings plunge

Thoratec (NSDQ:THOR) yesterday said its 3rd-quarter profits plunged some 85%, missing forecasts, and dimmed its outlook for the rest of the year.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Allergan CEO Pyott steps down from Edwards Lifesciences board | Personnel Moves

October 7, 2014 by Brad Perriello

Allergan CEO David Pyott steps down from the board at Edwards Lifesciences to devote more time to his chief executive duties.

Allergan CEO Pyott steps down from Edwards Lifesciences board | Personnel Moves

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Thoratec ousts Burbach, brings Grossman back

September 22, 2014 by Brad Perriello

Thoratec ousts CEO Gary Burbach and replaces him with predecessor Keith Grossman.

Thoratec's new study, $30M buyback can't stave off Wall Street exodus after dismal Q2

August 7, 2014 by Arezu Sarvestani

Thoratec's stock drops more than 26% in after-hours trading after the company lowers its full-year guidance on a dreary 2nd quarter.

New study, $30M buyback can't save Thoratec from Wall Street exodus after dismal Q2

Circulatory devices maker Thoratec (NSDQ:THOR) took a major hit yesterday as a bleak 2nd-quarter reports and a lowered outlook on the year sent its stock into a nosedive.